濮阳东方医院看早泄很便宜(濮阳东方男科医院技术非常专业) (今日更新中)

If you're on the hunt for a bike rack and can't find one, you're not alone. Bike racks are currently low stock, out of stock or backordered as bike sales soar amid the novel coronavirus pandemic.High demand for bike racks and installation is putting it lightly.“U-Haul is the number one installer of after-market hitches in the entire U.S., so we’ve got a hitch professional installing hitches, bike racks, trailer hitches, just about everything else you can imagine at almost all of our 2,000 company-owned stores, said Jeff Lockridge, with U-Haul International.“There’s enough customers asking for them to where the primary manufacturers have a backlog and that was the very reason that our hitch manager decided to expand our product line and go out and sign up more bike rack manufacturers to make sure we’ve got product quicker.”In fact, so many people want bike racks and hitches, June 2020 saw the biggest sales month in U-Haul’s 75-year history. Those June sales broke the May sales, which were also record-high. It also sent the U-Haul sales team looking for more companies to deliver more product.“We are understandably handcuffed a little bit by how quickly manufacturers can get product to us so that we can take care of our customers because people are wanting to get out and ride their bikes now,” Lockridge said.They expanded and now offering racks from 15 different companies.Also in high demand: U-Haul’s "contactless" system.“They can rent a truck, pick it up, entirely on their cell phone without having contact with our team members,” explained Lockridge. 1583

How accurate are the coronavirus tests used in the U.S.?Months into the outbreak, no one really knows how well many of the screening tests work, and experts at top medical centers say it is time to do the studies to find out.When the new virus began spreading, the Food and Drug Administration used its emergency powers to OK scores of quickly devised tests, based mainly on a small number of lab studies showing they could successfully detect the virus.That’s very different from the large patient studies that can take weeks or months, which experts say are needed to provide a true sense of testing accuracy.The FDA’s speedy response came after it was initially criticized for delaying the launch of new tests during a crisis and after the Centers for Disease Control and Prevention stumbled in getting its own test out to states.But with the U.S. outbreak nearly certain to stretch on for months or even years, some experts want the FDA to demand better evidence of the tests’ accuracy so doctors know how many infections might be missed.There have been more than 2 million confirmed coronavirus cases in the U.S. and more than 115,000 deaths, according to data compiled by Johns Hopkins University. Cases in nearly half of U.S. states are rising.In recent weeks, preliminary findings have flagged potential problems with some COVID-19 tests, including one used daily at the White House. Faulty tests could leave many thousands of Americans with the incorrect assumption that they are virus-free, contributing to new flare-ups of the disease as communities reopen.“In the beginning, the FDA was under a lot of pressure to get these tests onto the marketplace,” said Dr. Steven Woloshin of Dartmouth College, who wrote about the issue in the New England Journal of Medicine last week. “But now that there are plenty of tests out there, it’s time for them to raise the bar.”The FDA said in a statement that it has already asked multiple test makers to do follow-up accuracy studies, although it didn’t say for how many of the more than 110 authorized screening tests. The agency also said it is tracking reports of problems. Accuracy has also been an issue with blood tests that look for signs of past infections.No screening test is 100% accurate. So details on accuracy are routinely provided for tests of all types, including seasonal flu, hepatitis, HIV and cancers. For example, rapid flu tests are known to miss 20% or more of all cases, a factor doctors weigh when treating patients who have symptoms but test negative.For now, most COVID-19 tests in the U.S. don’t give data on real-world performance, including how often the tests falsely clear patients of infection or falsely detect the virus. That information is lacking for all but a few of the roughly 80 commercial screening tests available, according to an Associated Press review.The government’s emergency authorization process “requires a lower level of evidence,” the agency said. Makers need only show that a test “may be effective” instead of the usual requirement to demonstrate “safety and effectiveness.” They would have to meet that higher threshold once the U.S. government declares the emergency over.Many of the commercial test makers submitted results from 60 samples, the minimum number required and mostly used lab-produced specimens of the virus. The FDA now recommends the use of nasal swabs or other real samples from people screened for coronavirus.Experts say larger patient studies patients are needed to assess a test’s true performance.Lab testing bears little resemblance to actual — sometimes imperfect — conditions at hospitals, clinics and testing sites noted Dr. Robert Kaplan of Stanford University.“You’re testing people in parking lots, the patients themselves are extremely anxious and often unable to follow instructions,” said Kaplan, a former associate director of the National Institutes of Health.Kaplan and others say those differences could explain why some tests are not performing as expected.Last month, the FDA warned doctors of a potential accuracy problem with Abbott Laboratories’ rapid ID Now test, which delivers results in roughly 15 minutes. The test has been lauded by President Donald Trump and used to screen the president, his staff and visitors to the White House.The FDA alert followed a preliminary report by New York University that found Abbott’s test missed between a third to one-half of infections caught by a rival test in patients screened for the virus.Abbott rejected the findings, saying the researchers did not follow the instructions for using its test. The company pointed to alternate patient studies, including its own, that have found the test successfully detects between 91% and 95% or more of virus cases when compared to other tests.But similar problems with ID NOW’s accuracy have been flagged in preliminary reports by researchers at Stanford University, Loyola University and the Cleveland Clinic.For now, the FDA is requiring Abbott to conduct follow-up studies in several different patient groups.The FDA’s emergency standards “are still high but there is a significant difference in the body of work that what would go into a submission under the normal process,” said Abbott vice president John Hackett. “Our normal process takes years to bring these out.”Requiring bigger studies of all coronavirus tests could provide valuable information, but it could also strain the FDA’s already stretched staff and resources, said Dr. Daniel Schultz, former director of the FDA’s medical device center.Dr. Colin West of the Mayo Clinic worries doctors and patients have put too much confidence in the current crop of tests, when an unknown number of patients with COVID-19 are likely receiving false negative results.Even a modest error rate can have grave consequences during an outbreak like COVID-19. West gives the example of a test that is 95% accurate at detecting the virus and is used on 1 million people. That would still result in 50,000 people being incorrectly told that they don’t have the virus.“The negative test does not mean that I’m off the hook,” West said. “We just need to maintain that level of vigilance until we have a better sense of how good these tests really can be.”___Follow Matthew Perrone on Twitter: @AP_FDAwriter.___Follow AP pandemic coverage at http://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6604

I believe we should abolish the Electoral College and select our president by the winner of the popular vote, same as every other office.But while it still exists, I was proud to cast my vote in New York for Joe Biden and Kamala Harris. pic.twitter.com/th9qebu9ka— Hillary Clinton (@HillaryClinton) December 14, 2020 330

If the lyrics to "Let It Go" have been stuck in your head since 2013's "Frozen," new songs are right around the corner.Kristen Bell, who voices Anna, the younger sister of Princess Elsa [Idina Menzel] from the hit animated Disney film, shared a "Frozen 2" update on Thursday during an appearance on "Ellen.""I have recorded the movie," Bell said. "There will be edits before it's finished. I know the songs, I know the story. It's very good!"The film also features the return of Josh Gad [Olaf] and Jonathan Groff [Kristoff]."Frozen" grossed more than billion in the worldwide box office and became Disney's highest-grossing animated film of all time."Frozen 2" releases in theaters November 27, 2019.  718

If you own a 2018 or 2019 Jeep Wrangler, get ready for a recall. According to documents posted to the JL Wrangler Forum, Fiat-Chrysler will soon be launching a recall that covers “certain” 2018-19 Wranglers because a faulty weld in the frame can cause a sudden crash.More specifically, the documents state some of the vehicles may have been built “with a front bar bracket weld located off the seam potentially resulting in the bracket separating from the frame.” If that happens, there may be a reduction in steering response, resulting in a crash without warning.At the time of this story, car owners had not yet been notified and the recall hasn’t been made official on the National Highway Traffic Safety Administration’s website, but the posted documents show dealerships are aware of the impending recall. Some of the vehicles involved in the recall have actually not even been sold yet, so dealerships are being told to withhold sales.  991

来源：资阳报